Literature DB >> 12105857

Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production.

Nobuyuki Enomoto1, Yoshiyuki Takei, Miyoko Hirose, Kenichi Ikejima, Hiroto Miwa, Tsuneo Kitamura, Nobuhiro Sato.   

Abstract

BACKGROUND & AIMS: Sensitization of Kupffer cells (KCs) to lipopolysaccharide (LPS) and overproduction of tumor necrosis factor (TNF) alpha are critical for progression of alcoholic liver injury. Thalidomide has been shown to suppress TNF-alpha production from macrophages. Accordingly, the purpose of this study was to determine whether thalidomide could prevent alcohol-induced liver injury.
METHODS: Rats were given ethanol (5 g/kg body wt) and thalidomide (5 mg/kg) once every 24 hours intragastrically. To assess the sensitization of Kupffer cells, LPS (5 mg/kg intravenously) was administered and liver histology was evaluated 24 hours later. KCs were isolated after 4 weeks of ethanol treatment and intracellular Ca2+ ([Ca2+]i) was measured using fura-2, whereas TNF-alpha was evaluated by reverse-transcription polymerase chain reaction and enzyme-linked immunosorbent assay. CD14 was determined by Western and fluorescence staining.
RESULTS: Treatment with ethanol for 8 weeks caused marked steatosis, necrosis, and inflammation in the liver. These pathologic parameters were diminished markedly by treatment with thalidomide. In the 4-week ethanol group, the LPS-induced liver damage was aggravated and KCs were sensitized to LPS. Coadministration of thalidomide with ethanol prevented the KC sensitization completely. Furthermore, thalidomide abolished the LPS-induced increase in CD14 expression and [Ca2+]i elevation in KCs. Gut permeability was increased about 10-fold after 4 weeks of ethanol exposure, which was not affected by thalidomide. Moreover, thalidomide reduced the LPS-induced TNF-alpha production by KCs by decreasing TNF-alpha messenger RNA.
CONCLUSIONS: These results collectively indicate that thalidomide prevents alcoholic liver injury through suppression of TNF-alpha production and abolishment of KC sensitization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12105857     DOI: 10.1053/gast.2002.34161

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  23 in total

Review 1.  Zinc and liver disease.

Authors:  Mohammad K Mohammad; Mohammad K Mohommad; Zhanxiang Zhou; Matthew Cave; Ashutosh Barve; Craig J McClain
Journal:  Nutr Clin Pract       Date:  2012-02       Impact factor: 3.080

2.  Targeting the gut barrier for the treatment of alcoholic liver disease.

Authors:  Zhanxiang Zhou; Wei Zhong
Journal:  Liver Res       Date:  2017-12

3.  Molecular pathway-specific 99mTc-N-(3-bromo-2,4,6-trimethyacetanilide) iminodiacetic acid liver imaging to assess innate immune responses induced by cell transplantation.

Authors:  Brigid Joseph; Kuldeep K Bhargava; Gene G Tronco; Christopher J Palestro; Sanjeev Gupta
Journal:  Nucl Med Commun       Date:  2009-02       Impact factor: 1.690

4.  Osteopontin binding to lipopolysaccharide lowers tumor necrosis factor-α and prevents early alcohol-induced liver injury in mice.

Authors:  Xiaodong Ge; Tung-Ming Leung; Elena Arriazu; Yongke Lu; Raquel Urtasun; Brian Christensen; Maria Isabel Fiel; Satoshi Mochida; Esben S Sørensen; Natalia Nieto
Journal:  Hepatology       Date:  2014-03-01       Impact factor: 17.425

5.  The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice.

Authors:  Aimin Xu; Yu Wang; Hussila Keshaw; Lance Yi Xu; Karen S L Lam; Garth J S Cooper
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

6.  Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis.

Authors:  R P Mookerjee; S Sen; N A Davies; S J Hodges; R Williams; R Jalan
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

7.  Toll-like receptors in the pathogenesis of alcoholic liver disease.

Authors:  Jan Petrasek; Pranoti Mandrekar; Gyongyi Szabo
Journal:  Gastroenterol Res Pract       Date:  2010-08-17       Impact factor: 2.260

8.  Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide.

Authors:  Evangelos J Giamarellos-Bourboulis; Helen Poulaki; Nikolaos Kostomitsopoulos; Ismene Dontas; Despina Perrea; Panayotis E Karayannacos; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

9.  Influence of Kupffer cells on hepatic signal transduction as demonstrated by second messengers and nuclear transcription factors.

Authors:  Hong Ding; Jie-An Huang; Jing Tong; Xin Yu; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

10.  Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.

Authors:  Ganesan Keerthivasan; Yang Mei; Baobing Zhao; Ling Zhang; Chad E Harris; Juehua Gao; Ashley A Basiorka; Matthew J Schipma; James McElherne; Jing Yang; Amit K Verma; Andrea Pellagatti; Jacqueline Boultwood; Alan F List; David A Williams; Peng Ji
Journal:  Blood       Date:  2014-06-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.